These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 410110)

  • 1. Current status and future role of health screening.
    North AF
    South Med J; 1977 Oct; 70(10):1232-6. PubMed ID: 410110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cost analysis of community screening for diabetes in the central Wisconsin Medicare population (results from the MetaStar pilot project in Wausau).
    Lee DS; Remington P; Madagame J; Blustein J
    WMJ; 2000 Jun; 99(3):39-43. PubMed ID: 10927980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
    Wolf MS; Fitzner KA; Powell EF; McCaffrey KR; Pickard AS; McKoy JM; Lindenberg J; Schumock GT; Carson KR; Ferreira MR; Dolan NC; Bennett CL
    J Clin Oncol; 2005 Dec; 23(34):8877-83. PubMed ID: 16314648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and benefits of prostate cancer screening. Investigators of the American Cancer Society--National Prostate Cancer Detection Project.
    Littrup PJ; Goodman AC
    In Vivo; 1994; 8(3):423-7. PubMed ID: 7803728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening.
    Soderstrom L; Woods WG; Bernstein M; Robison LL; Tuchman M; Lemieux B
    J Natl Cancer Inst; 2005 Aug; 97(15):1118-24. PubMed ID: 16077069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost analysis of the National Breast and Cervical Cancer Early Detection Program: selected states, 2003 to 2004.
    Ekwueme DU; Gardner JG; Subramanian S; Tangka FK; Bapat B; Richardson LC
    Cancer; 2008 Feb; 112(3):626-35. PubMed ID: 18157831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
    Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-benefit analysis of Helicobacter pylori screening.
    Leivo T; Salomaa A; Kosunen TU; Tuominen R; Färkkilä M; Linna M; Sintonen H
    Health Policy; 2004 Oct; 70(1):85-96. PubMed ID: 15312711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of type 2 diabetes screening: results from recently published studies.
    Icks A; Rathmann W; Haastert B; John J; Löwel H; Holle R; Giani G;
    Gesundheitswesen; 2005 Aug; 67 Suppl 1():S167-71. PubMed ID: 16032536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. School-based screening for scoliosis: is it cost-effective?
    Thilagaratnam S
    Singapore Med J; 2007 Nov; 48(11):1012-7. PubMed ID: 17975691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: costs and effectiveness of alternative interventions.
    Mrus JM; Biro FM; Huang B; Tsevat J
    Arch Pediatr Adolesc Med; 2003 Jul; 157(7):696-702. PubMed ID: 12860793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits.
    Marshall KG
    CMAJ; 1996 Jun; 154(12):1837-43. PubMed ID: 8653643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening in liver disease: report of an AASLD clinical workshop.
    Adams PC; Arthur MJ; Boyer TD; DeLeve LD; Di Bisceglie AM; Hall M; Levin TR; Provenzale D; Seeff L
    Hepatology; 2004 May; 39(5):1204-12. PubMed ID: 15122748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outcome and future of mass screening for uterine cervical cancer].
    Noda K; Tejima K
    Gan No Rinsho; 1983 May; 29(6):483-7. PubMed ID: 6410103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing and testing a cost-assessment tool for cancer screening programs.
    Subramanian S; Ekwueme DU; Gardner JG; Trogdon J
    Am J Prev Med; 2009 Sep; 37(3):242-7. PubMed ID: 19666160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.